Literature DB >> 16100948

Current concepts and controversies in the treatment of parenchymal brain metastases: improved outcomes with aggressive management.

Gopal K Bajaj1, Lawrence Kleinberg, Stephanie Terezakis.   

Abstract

The multimodality management of brain metastases has undergone significant refinement in the last decade. Although brain metastases remain a significant source of morbidity and mortality for many cancer patients, aggresive management has led to pronounced gains in neurological functioning, disease free survival and overall survival compared to standard treatment regimens consisting of only whole brain radiation therapy. Representative studies reviewing the role of aggressive management approaches including surgical resection with or without whole brain radiation therapy or non-surgical approaches employing stereotactic radiosurgery alone or in combination with whole brain radiation therapy are highlighted. Additionally, the emerging role of systemic agents showing distinct clinical activity in patients with brain metastases are also discussed. As we continue to gain advances in systemic therapies for metastatic disease, local control of brain metastases in these patients is likely to become more critical in improving survival and quality of life, thereby calling for a more aggressive multi-modal approach to this population of patients.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16100948     DOI: 10.1081/cnv-58889

Source DB:  PubMed          Journal:  Cancer Invest        ISSN: 0735-7907            Impact factor:   2.176


  2 in total

1.  Combined Open and Endoscopic Endonasal Skull Base Resection of a Rare Endometrial Carcinoma Metastasis.

Authors:  Melissa M Stamates; John M Lee; Ryan T Merrell; Michael J Shinners; Ricky H Wong
Journal:  J Neurol Surg Rep       Date:  2018-02-22

2.  Autumn Royal and Ribier Grape Juice Extracts Reduced Viability and Metastatic Potential of Colon Cancer Cells.

Authors:  Manuel Valenzuela; Lorena Bastias; Iván Montenegro; Enrique Werner; Alejandro Madrid; Patricio Godoy; Mario Párraga; Joan Villena
Journal:  Evid Based Complement Alternat Med       Date:  2018-01-14       Impact factor: 2.629

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.